诚意药业：帕拉米韦注射液获得药品注册证书

Core Viewpoint - Chengyi Pharmaceutical (603811.SH) has received approval from the National Medical Products Administration for the registration certificate of Palivizumab injection, which is indicated for the treatment of influenza A or B [1] Company Summary - Chengyi Pharmaceutical has recently announced the approval of Palivizumab injection, expanding its product offerings in the antiviral medication market [1] - The approval signifies a potential growth opportunity for the company in the influenza treatment segment [1] Industry Summary - The approval of antiviral medications like Palivizumab is crucial in addressing seasonal influenza outbreaks, highlighting the importance of effective treatments in public health [1] - The market for influenza treatments is expected to grow, driven by increasing awareness and demand for effective antiviral therapies [1]